Prescient Therapeutics (ASX:PTX) EV-to-EBITDA : -2.45 (As of Apr. 25, 2024)

Prescient Therapeutics EV-to-EBITDA Chart

Prescient Therapeutics Annual Data
	Trend	Jun13	Jun14	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23
EV-to-EBITDA		Get a 7-Day Free Trial					-1.40	-4.24	-34.10	-17.45	-4.38

Prescient Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															-	-17.45	-	-4.38	-

Competitive Comparison of Prescient Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Prescient Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prescient Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's EV-to-EBITDA falls into.

Prescient Therapeutics EV-to-EBITDA Calculation

Prescient Therapeutics's EV-to-EBITDA for today is calculated as:

Prescient Therapeutics's current Enterprise Value is A$28.27 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prescient Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-11.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics  (ASX:PTX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Prescient Therapeutics's PE Ratio for today is calculated as:

Prescient Therapeutics's share price for today is A$0.058.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prescient Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.010.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Prescient Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Prescient Therapeutics (ASX:PTX) Business Description